best posit earli mr-linac adopt
initi buy pt
buy thesi base best posit captur earli mr-
linac adopt due first mover advantag grow bodi clinic
evid competit advantag elekta small win translat
big gain clear pathway run near-term launch buy
pt long-term see upsid broader adopt
mr-linac possibl next best thing radiat oncolog mr-linac
latest emerg technolog trend radiat oncolog space combin
mri linear acceler onto singl platform combin technolog
improv tumor visibl radiat dose earli clinic evid suggest combo
lead surviv benefit mani cancer includ pancrea breast abdomen
market size earli adopt potenti disrupt overtim
bottom model top us cancer center point capac system
earli adopt equat capit opportun midpoint
rang evid key cancer advanc mr-linac could prove disrupt
global linac instal base share translat capit
thesi best posit captur earli mr-linac adopt wave
best posit captur earli mr-linac adopt due continu launch setback
design limit elekta mr-uniti expand clinic evid key cancer
smaller bunker size favor price vs mr-uniti
initi model forecast order instal street high
ahead elekta target
proprietari work radonc survey posit conduct survey
us-bas radiat oncologist gaug demand/purchas trend vray mridian
ektab mr feedback heavili weight toward mridian due benefit
footprint size cost util mr magnet sampl point toward
potenti order next month
initi buy pt upsid use modest share assumpt
outlook call total instal global linac market pt
sale target howev see upsid use share
target could prove conserv depend clinic data competit
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
prospect pancreat studi yield similar result
studi breast cancer eventu lung prostat yield
similar result pancreat studi
mr-linac penetr gradual increas market
share global linac market
mridian maintain competit advantag mr-uniti
mridian mr-uniti gradual drift share
base pt use ev/sal
prospect pancreat studi yield similar result
studi breast cancer eventu lung prostat yield
similar result pancreat studi
mr-linac penetr gradual increas
market share global linac market
mridian captur instal base case
acquir mr-linac becom larger portion
upsid pt base mridian instal
compar retrospect pilot studi
studi breast cancer lung prostat delay
mr-linac remain nich technolog use
academ center due lack clinic evid workflow
cost barrier
mr-uniti captur greater share global mr-
linac instal base case
downsid pt base cash backlog
buy thesi base co best
posit captur earli mr-linac adopt due
first mover advantag grow bodi clinic
evid competit advantag elekta
differenti built bottom
model top cancer center us suggest
capac system
differenti survey work mr-linac
adopt point mridian order next year
supplement kol check cancer center
ny industri confer astro estro
potenti astro follow full-readout
public time-frame
clinic data breast cancer lung and/or prostat
present medic meet astro estro
unforeseen announc
posit potenti target consolid
nol
page
pleas see import disclosur inform page report
launch
buy rate pt buy
thesi base first-mov
advantag us eu
expand clinic evid
launch setback elekta
bottom analysi
could system rang
valu
commit mridian linac
order next month
pt base
outlook
ahead street
forecast upsid pt base
global share
initi coverag buy rate pt tsr
current sole provid mr-guid radiat therapi solut sever key
market includ us eu pt base outlook total
order instal base growth system exit upsid pt base
outlook forecast instal base reach system global
share could prove conserv depend clinic data competit
snapshot buy thesi valuat overview risk share
mr-linac potenti next big thing radiat therapi holi grail
better visual higher dose
concentr cancer cell spare healthi tissu despit earli
launch cycl mr-linac alreadi demonstr improv
theori lead better treatment outcom clinic studi support
elekta ektab hold consortium member begin show tumor
volum surviv benefit key cancer includ pancrea consortium led
brain ektab consortium led breast abdomin among other
bottom review top rank us cancer institut nci design
cancer center dirac databas suggest earlier adopt mr-linac
repres unit versu rang ektab assum multi-
system order lead center use asp midpoint rang
valu segment total opportun evid advanc key
cancer mr-linac could prove disrupt global linac instal base
share translat capit opportun overtim
first mover advantag tech benefit competit
current sole provid mr-enabl technolog approv
countri inclus fda ce mark clearanc head start continu
extend setback sole competitor elekta check suggest late
entri mr-uniti vray mridian linac also sever benefit mr-uniti
support faster adopt even competit scenario includ
elimin distort favor price vs ektab
proprietari survey work captur order
respond practic high volum center averag annual treatment
multipl bunker expect purchas across sampl heavili weight toward
mridian due footprint size cost util mr magnet sampl
indic commit mridian order next month
top-lin forecast exce street estim vs street
assum captur order acceler instal cycl
outlook call total instal global share pt
sale forecast howev see upsid use share target
risk buy thesi clinic trial outcom mr-uniti competit
page
pleas see import disclosur inform page report
flow backlog instal
key
indic vray
oper success henc share
price forese futur
posit clinic data cost
reduct need mass
estro/astro event drive
despit on-going ektab setback
expect mr-uniti eventu gain
mr-uniti mridian still
much debat
instal financi result
risk stock catalyst
earli adopt mridian order backlog instal cycl quarterli
mridian order flow backlog primari lead indic success
vray busi model henc like key driver share forese
futur look ahead outer year forecast asid order win rate backlog
growth rate backlog convers specif time initi contract sign
system instal primari revenu growth factor current model assum
ttm backlog convers improv today support
suffici exist capac across intern extern instal team
broader mr-linac adopt data cost concern ektab agre
initi adopt mr-linac limit lead academ cancer center
well fund long-term view data prove cost come
mr-linac stand cannib global linac market repres
substanti reduc price occur ektab stand
benefit greatli howev data fall short cost remain elev mr-linac remain
nich technolog proven costli emerg area proton therapi
clinic data readout medic meet tradeshow key area
mridian explor better outcom versu standard care pancreat
breast cancer follow posit retrospect analysi pancreat cancer
show overal surviv os benefit multi-sit prospect studi
enrol across sever lead cancer site us earli breast studi thoma et al
show reduct toxic faster treatment time better cosmesi
present estro publish journal radiat oncolog look ahead
expect pivot data readout releas either estro astro industri
lead medic meet eu us
competit elekta mr-uniti receiv ce mark fda clearanc
nearli develop cycl elekta recent secur ce mark clearanc mr-
uniti system june clear way sale clinic use europ despit
recent entri mr-uniti still design flaw rel mridian mainli around
interfer mr scanner linear gener well patient
mobil despit limit still see mr-uniti posit gain socket
base elekta long-stand presenc marketplac prove
greater reflect order forecast mridian outlook
share impact
econom roi reimburs hospit capital-expenditure risk mr-linac
adopt cost least greater versu standard linac solut stabil
reimburs hospit capit budget paramount near long-term
adopt reimburs landscap us current conduc mr-linac
adopt given addit compens treatment plan combin need
fewer fraction reimburs shift toward bundl model potenti
alloc fund away radiat therapi roi mr-linac impact
combin shift hospit capit budget would limit mr-linac adopt
quarterli earn given vray statu earli commercial-stag compani
oper capit equipment-depend model quarterli result like tend
fluctuat forese futur view ttm perform busi
relev consid
lengthi sale/implement cycl
nonetheless fluctuat quarterli perform like remain catalyst
volatil share forese futur
page
pleas see import disclosur inform page report
mr-linac first unveil
estro confer turkey
use mr imag guidanc
first discuss due limit
mr offer sever advantag
less radiat exposur
engin hurdl result
lengthi develop cycl mr linac
combin magnet reson mr imag linear acceler singl
platform small feat technolog make push
toward mr respons limit exist imag modal mainli
cone beam comput tomographi cbct still consid standard care
imag guidanc radiat therapi today briefli explor limit
cbct advantag mr develop hurdl provid timelin key event
technolog breakthrough radiat oncolog space goal
combin mr imag radiotherapi improv visibl cancer non-
cancer tissu treatment becom precis turn improv
outcom measur patient surviv although cbct offer superior imag qualiti
tradit ct provid high-qual imag soft tissu make difficult
visual tumor complex region bodi includ brain liver pancrea
kidney mani complex case use cbct even tumor visual
difficult distinguish cancer surround healthi tissu cbct also
limit track tumor region bodi continu motion
breath and/or swallow lastli cbct expos patient addit radiat
limit abil repeat scan treatment plan set motion
cbct use preced treatment mr imag potenti
solv limit direct comparison cbct mr offer superior soft-
tissu visual larger varieti function imag capabl
expos patient addit radiat capabl offer sever potenti treatment
workflow outcom benefit describ detail
despit mr clear benefit featur cbct develop singl
system combin radiat gener proven difficult biggest
technolog hurdl manag interact two technolog
sinc magnet field gener mr scanner interfer acceler electron
radio frequenc produc linear acceler distort mr imag qualiti
treatment plan also prove hurdl due need assign electron densiti
mr scan dose calcul issu develop
cycl mr-guid radiotherapi lengthi technolog first discuss
estro confer turkey follow initi prototyp
elekta philip success secur initi market clearanc first
mridian cobalt later mridian linac time-frame
chart mr-guid radiat therapi timelin key develop
page
pleas see import disclosur inform page report
mr-guid radiotherapi first discussedestro elekta philip begin mr-linac prototyp complet instal umc siemen develop agreementu mr linac consortium createdu eu cobalt market clearancesu philip prototyp installationmd linac market clearancesu market clearanc mr-linac product
solv
engin hurdl around mr
linac allow integr onto
overcom hurdl lie
despit elekta lead mr-linac develop cycl first collabor design
unveil elekta philip umc netherland first solv
two signific engin hurdl integr mr linac onto singl
platform linac radiofrequ interfer oper mri mri magnet
interfer oper linear acceler
solv first hurdl develop coat technolog similar
use militari aircraft reflect absorb microwav order prevent radar
beam bounc back radar station mridian intern system use similar
coat reflect absorb output linear acceler order prevent
interfer mri result mridian produc mri imag free
linac distort
second hurdl mri magnet field interfer oper linac proven
difficult manufactur solv core obstacl mani linac
compon oper properli place close rang high-pow
superconduct magnet use mr scanner captur patient imag despit
limit close placement mr magnet linac compon necessari creat
system compact enough fit exist radiat therapi vault turn lower
total acquisit cost hospit clinic elekta bold approach
chose stronger magnet mr scanner mr-uniti result sever
launch setback potenti workflow issu check indic stronger magnet
henc greater interfer result fewer imag everi second versu mridian
frame per second overcam challeng creat magnet shield
shell creat void magnet field design featur allow linac
oper mridian gantri magnet field present mridian design
ip protect patent estat extend inclus file
chart mr-linac combin mr imag radiat therapi singl platform
page
pleas see import disclosur inform page report
mr-linac broadli mridian
specif carri advantag soft
tissu visual dose
better soc visibl dose adapt
radiat oncolog treatment modal rt imrt srs/sbrt consist
seri fraction beam dose tumor administ singl multipl week
key limit exist radiat therapi solut relianc anatom
snapshot tumor structur bodi begin intermitt
treatment seri replac cbct mri mr-linac system better soft-
tissu visual capabl allow physician better distinguish tumor
healthi tissu abl locat track tumor precis allow better
beam precis healthi tissu cell spare featur combin improv dose
disposit tumor lower risk toxic healthi tissu
chart medic imag prostat use cone-beam ct
chart medic imag prostat use mri w/mridian
allow better dose conform
spare healthi tissu
although new radiat treatment technolog evolv improv
featur none capabl adapt therapi mridian system cobalt
linac first radiat therapi technolog capabl perform adapt
radiotherapi dose shape need cours therapi base shift
tumor posit shape proxim organ
page
pleas see import disclosur inform page report
pancreat cancer signific
dose reduct breast two earli
aim
retrospect analysi analyz
benefit mridian on-tabl
adapt therapi advanc stage
earli retrospect data pancrea show potenti nearli percentag point
benefit overal surviv os probabl use adapt rt mridian base
data consortium lead cancer center enrol multi-sit prospect studi
explor benefit toxic os earli breast cancer data thoma et al show
reduct radiat dose signific treatment time reduct better
cosmesi provid deeper dive timelin follow-on readout
retrospect pancreat cancer studi prospect enrol
interest mridian along mani radiat oncolog commun
heighten come astro confer present
compel retrospect data show nearli percentag point benefit
median os patient treat adapt radiat therapi studi
therapi improv surviv inoper pancreat cancer patient led dr parag
parikh associ professor radiat oncolog washington univers
present poster podium present astro meet
aim analyz perceiv benefit adapt radiat therapi sbrt
perform without on-tabl adapt featur mridian idea
account inter-day tumor shift physician washington univers observ
averag cours therapi signific pancreat
cancer case sinc shift chang tumor location/size/shap put vital
organ around pancrea stomach duodenum small intestin risk toxic
cellular destruct studi demonstr on-tabl adapt featur
mridian effect account chang tumor location/size/shap correct
treatment plan mridian on-tabl adapt therapi radiat oncologist
institut adjust treatment plan success avoid exposur surround
organ reduc unnecessari toxic associ advers event
data show mridian on-
tabl adapt therapi allow
higher dose limit toxic
abil adapt treatment cours chang tumor location/shape/s
allow two signific treatment benefit across case captur
retrospect analysi higher radiat dose lower record overal toxic
higher radiat dose deliv averag maxb deliv gray
gy normal use treat advanc liver lung case
lower record toxic level despit higher dose toxic much
lower due better disposit avoid healthi tissu treatment maxb
case experi grade gi toxic observ wherea
treatment maxb observ typic pancreat
page
pleas see import disclosur inform page report
turn led overal
surviv os benefit
os doubl use mridian on-tabl adapt therapi
data clearli show patient undergo non-adapt radiat treatment
significantli lower chanc surviv post-treat
wherea patient get on-tabl adapt radiat therapi improv chanc
surviv almost studi found stereotact dose regimen
guid mr imag daili on-line adapt led significantli
prolong patient surviv result favor low toxic
chart retrospect analysi local advanc
pancreat cancer ucla uw vumc washington
chart retrospect analysi local advanc
pancreat cancer ucla uw vumc washington
follow data readout conjunct research consortium
guid adapt radiat therapi smart primari outcom measur
overal record toxic secondari outcom measur overal surviv os
assum match retrospect studi depend cadenc
enrol last-in-man earli readout data could coincid astro
final readout either estro astro
chart consortium enrol prospect pancreat cancer studi
adopt path mridian henc
readout serv key stock
page
pleas see import disclosur inform page report
women cancer centerboston ford cancer institutedetroit du cancer de montpelliermontelli paoli calmettesmarseil center cancer research palo south campu cancer center tampa cancer institut baptist southern cancer center ncc tokyo hospitalnew york uf cancer centerorlando agostino gemelli universita cattolica del sacro cuor gemelli artrom nation univers hospit snuh seoul south comprehens cancer center uhealthmiami california jonsson comprehens cancer centerlo angel wisconsin carbon cancer center madisonmadison univers medic centeramsterdam univers siteman cancer center barnes-jewish hospitalst loui linacslocationcount
earli data use mridian perform
radiat dose
volum reduct treatment
time better cosmesi
mridian adapt therapi acceler partial-breast irradi apbi
breast cancer anoth set mridian show promis data
earli stage studi also washington univers present estro
recent publish intern journal radiat oncolog studi led
dr maria thoma examin intra-fract motion breast surgic caviti
assess deliv versu plan radiat dose earli breast cancer case stage
purpos studi explor better radiat altern perform
acceler partial-breast irradi apbi altern whole breast irradi
prefer treatment altern partial complet mastectomi apbi sever
advantag whole breast irradi includ less treatment time deliv
day versu week decreas radiat volum lower toxic risk despit
advantag apbi perform extern beam radiat shown higher post
treatment toxic level versu whole breast radiat due visual limit
intra-fract tumor motion accordingli studi hypothesi mridian could
solv limit make apbi viabl treatment option versu whole
breast radiat studi result compel minim observ intra-fract
motion median radiat plan target volum ptv reduc mean
differ plan deliv dose less across mridian
earli apbi data replic
large-scal studi would
serv catalyst expans
broader commun hospit
data replic larger pivot studi radiat oncologist like
reli heavili apbi versu whole breast therapi turn push tumor board even
favor radiat surgeri mastectomi shift earli breast patient
toward apbi increas patient volum reduc hospit in-day
combin favor hospit payer patient apbi result lower
out-of-pocket cost fewer hospit in-day less time better potenti
outcom better dose disposit lower surround toxic data
pancreat studi readout carri signific due treatment implic
set altern follow-on apbi studi carri signific
standpoint mr-linac given much higher preval breast case new case
per year versu pancrea signific consid major
radiat therapi perform commun hospit breast case accordingli see
posit breast studi readout either mridian mr-uniti signific catalyst
page
pleas see import disclosur inform page report
advantag amass
grow dosier clinic evid
mridian mani cancer type
mridian substanti data lead mr-uniti
although earli data pancrea breast compel amass sizabl
dossier singl multi-sit studi demonstr benefit numer cancer
type includ prostat lung thorax gi cervic studi led earli
mridian adopt facilit first mover advantag
detail regulatori clearanc order announc section similar earli effort
elekta compani also establish research develop consortium
collect aim studi workflow treatment benefit mridian
either isol comparison treatment modal includ soc radiat
modal combin therapi chemo/radi surgery/radi asid
known earli mridian adopt member lead academ site capabl
multipl system purchas importantli influenc treatment guidelin
overtim aim foster evidence-bas practic mri-guid radiat therapi
on-line adapt radiat therapi real-tim soft-tissu track scientif
collabor rapid dissemin clinic find
list studi enrol conduct member updat
sever studi present astro estro inclus
ucla real-tim adapt sbrt studi pancrea vumc smart studi local advanc
pancrea tumor site washington univers phase studi treat ultra-centr thorax
lesion univers wisconsin studi examin respons rate gi tumor
chart show signific clinic data pancrea lung breast prostat gastrointestin cervic cancer
elekta minim clinic evid
mr-uniti platform due
launch set-back fda clearanc
expect howev
check suggest could push
late earli
elekta develop process mr-uniti system close year
littl show way clinic data larg due design launch setback
look back astro mr-uniti present limit improv process
workflow analys oppos clinic outcom one year later astro
elekta present preliminari investig studi show shrinkag aggress
brain tumor patient investig look patient total feasibl
studi show mr-uniti could potenti allow target smaller tumor
page
pleas see import disclosur inform page report
institutionstudi namefocu cancerfindings/conclusionuclaoutcom util mri-guid real-tim adapt pancrea sbrtpancrea use sbrt mri-guid real-tim adapt replan lapc oligometastat pancrea tumor may offer improv lc decreas short-term long-term toxic vumc smart local advanc pancreat tumorspancrea advancedveri limit acut toxic well toler track sbrt target volum alway less differ motion length speedwashington univers st-louissmart ultra-centr thorax lesionslung smart allow ptv coverag improv and/or oar spare compar non-adapt sbrt may widen therapeut excel local control observ acut grade toxic winconsin-madisondifferenti respons rate gastrointestin tumor real-tim mri-guid radiat therapi opportun treatment individualizationgastrointestinalreal-tim mri guid radiotherapi allow adapt volumetr chang tumor vari depend tumor gej vs rectal data correl draw tailor treatment individu tumor snuhtreat qualiti intens modul radiat therapi compar volumetr modul arc therapi cervic cancercerv cancer owe target margin reduct capabl imrt plan favor vmat plan cervic cancer n/amagnet reson imag guid radiat therapi extern acceler partial-breast irradi evalu deliv dose intrafract caviti motionpartial-breastptv volum reduc minim intrafract motion observ less differ plan deliv dosevumc smart prostat cancerprostatedaili re-optim mandatori ensur proper coverag postat addit re-optim spare rectrum bladder fractionsgemellitoward tumor margin reduct track accuraci evalu mri-rt systemn/a system show encourag perform track sbrt target volum dose differ alway less differ motion length speed institutionstudi namefocu cancerfindings/conclusionsunnybrook centerpreliminari investig adapt glioblastoma radiat therapi use integr high-field patient analyz gtv shrunk day colleg wisconsindosimetr feasibl perop partial breast irradi prone posit use magnet reson linear acceleratorbreast mri-guid preop papbi could potenti allow treatment smaller volum breast tissu
mridian linac secur clearanc
us eu japan begin
versu mr-uniti ce
mark clearanc june
referenc earlier abl amass clinic data across numer
cancer type versu elekta mr-uniti system take advantag first mover
advantag across numer geographi receiv initi fda clearanc
mridian treatment plan deliveri softwar januari receiv
clearanc first gener mridian cobalt system follow
ce mark clearanc late mark initi market entri us
eu mr-enabl platform subsequ mridian cobalt gain sever
addit market clearanc south korea japan china
compani second gener platform mridian linac receiv ce mark clearanc late
fda clearanc earli recent mridian linac receiv
shonin clearanc earli make system avail clinic use across
three largest med-tech market us eu japan compar favor elekta
recent receiv ce mark clearanc mr-uniti june sever
setback timelin fda shonin clearanc remain unclear
chart list mridian cobalt mridian linac system regulatori clearanc
mridian backlog stand order
versu order mr-uniti
capit earli market clearanc secur contract win mani
lead cancer site across us eu japan earlier year compani
announc mileston surpass order mridian technolog
march stand order mridian system compar favor elekta
mr-uniti order book stand total order mani secur prior
receiv offici regulatori clearanc potenti put risk revers
page
pleas see import disclosur inform page report
linac receiv shonin approv japanes ministri labor welfar mhlw mridian linac linacreceiv fda clearanc mridian linac first two us system expect instal henri ford barnes-jewish ce mark linacreceiv ce mark clearanc mridian linac system us clearanc also submit cfda cobaltreceiv china fda cfda clearanc cobalt-bas mridian system repres china cowealth medic cobalt receiv shonin approv japanes ministri labor welfar mhlw cobalt-bas mridian system mfdssouth cobaltreceiv clearanc south korean ministri food drug safeti mfd cobalt-bas mridian system ce mark cobaltreceiv ce mark clearanc cobalt-bas mridian system cobaltreceiv fda cobalt-bas mridian system clearancecountri datetechnologyqualit commentari
chart list mridian system contract win purchas announc ytd
mridian also grow list
instal first-pati treat
mileston rel mr-uniti
perhap importantli initi order also success convert
backlog instal earli adopt site activ treat patient date
mridian success instal lead cancer site across us eu
japan instal figur time final instal also stack well versu
elekta mr-uniti convert unit backlog live site
chart list mridian system instal first patient treat announc ytd
page
pleas see import disclosur inform page report
technolog medic system aventura purchas mark purchas univers hospit zurichzurich devic met latest technolog requir fit premis replac devic rigshospitalet/herlev hospit denmark health system tender award includ mridian system standard linac varian edogawa hospitaltokyo receiv shonin approv august cobalt-bas mridian edogawa second order countri behind ncc univers clinic heidelberggermani research foundat dfg purchas mridian linac patient treatment univers clinic heidelberg nation cancer center ncc tokyo receiv shonin approv august cobalt mridian system ncc first order countri henri ford systemdetroit ford acquir mridian clinic studi non-clin research clearanc statu time annouc ington universityst loui cancer center barnes-jewish mark first site world begin studi mridian linac qualit commentarycenterregion countri datetechnolog systemsington universityst loui patient treatedmridian treatment second system first patient receiv mridian linac treatment treatedvu medic centeramsterdam patient treatedmridian month instal mridian linac vu medic centerunivers clinic heidelberg patient treatedmridian roughli two week instal univers clinic heidelbergunivers clinic heidelberg installationmridian first instal sinc receipt ce mark mridian linacington universityst loui installationmridian cancer center barnes-jewish hospit ington univers school complet mridian instal henri ford systemdetroit patient treatedmridian ford initi order announc septemb instal annoiunc june cancer center patient treatedmridian shonin approv august cobalt-bas mridian system initi contract win ncc septemb ford systemdetroit installationmridian announc releas cancer institut henri ford medic center-cottag gross point farm vu medic centeramsterdam installationmridian mark first mridian instal eu clinic treatment expect commenc spring qualit commentarycenterregion countri datetechnolog systemsev
clearanc june despit
mridian signific competit
futur order
potenti
competit analysi advantag mridian
mr-linac space offici transit market elekta recent receipt
ce mark clearanc mr-uniti least relat competit dynam across
us elekta still target fda clearanc mr-uniti howev recent check
suggest design issu specif on-going interfer mr scanner
radiat gener continu plagu mr-uniti result potenti fda
region clearanc push beyond late regardless time mr-
way one two avail mr-linac system market
result need technolog select hospit clinic mridian
mr-uniti market certainli split vari degre still see mridian
sever competit advantag mr-uniti support view
captur major order elekta least
head-to-head comparison see mridian sever clear competit
advantag versu mr-uniti function cost side equat
field strength use mridian allow less interfer oper linac imag
qualiti preserv use siemen compress imag technolog
on-tabl adapt therapi sustain mridian advantag mridian
abil continu mr imag treatment allow patent on-tabl
adapt therapi mr-uniti also market adapt solut
current capabl provid intermitt imag radiat session
lower up-front capit acquisit cost mridian vs mr-uniti mridian
price rang realiz price trend closer
past sever qs convers elekta maintain origin asp mr-
make expens midpoint vs mridian recent price
mridian smaller footprint lower total cost ownership vs mr-uniti
mridian footprint fit suggest vault size match hospit free
stand clinic vault sever industri player quot
vault reconstruct cost accommod mr-uniti tradit size vault
chart comparison mridian elekta uniti
page
pleas see import disclosur inform page report
